The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia

Haematologica

Volumn 90, Issue 11, 2005, Pages 1471-1476

  Thörn, Ingrid ^a   Olsson Strömberg, Ulla ^a   Ohlsen, Cecilia ^a   Jonsson, Anna Maria ^c   Klangby, Ulf ^b   Simonsson, Bengt ^a   Barbany, Gisela ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Sangtec Molecular Diagnostics   (Sweden)

^c University Hospital ^*

Author keywords

BCR ABL; CML; MRD; PAXgene; Real time PCR

Indexed keywords

IMATINIB;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANALYTICAL EQUIPMENT; ARTICLE; BLOOD SAMPLING; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EXTRACTION; FOLLOW UP; HUMAN; HUMAN CELL; MINIMAL RESIDUAL DISEASE; PHLEBOTOMY; REAL TIME POLYMERASE CHAIN REACTION; RNA PROCESSING; RNA STABILITY;

GENE EXPRESSION REGULATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; NEOPLASM, RESIDUAL; REAGENT KITS, DIAGNOSTIC; RNA STABILITY; RNA, MESSENGER;

EID: 27844455938     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013-34.
2. Hochhaus A. Detection and quantification of leukemia-specific rearrangements. Methods Mol Med 2002;68:67-96.
3. Gabert J, Beillard E, van der Velden V. H, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;17:2318-57.
4. Hochhaus A. Minimal residual disease in chronic myeloid leukaemia patients. Best Pract Res Clin Haematol 2002; 15:159-78.
5. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32.
6. Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Geurts van Kessel A, et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 1998;102:768-74.
7. Preudhomme C, Revillion F, Merlat A, Hornez L, Roumier C, Duflos-Grardel N, et al. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay. Leukemia 1999;13:957-64.
8. Barbany G, Hagberg A, Olsson-Stromberg U, Simonsson B, Syvanen A C, Landegren U. Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients. Clin Chem 2000;46:913-20.
9. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999;13:1825-32.
10. Stentoft J, Pallisgaard N, Kjeldsen E, Holm MS, Nielsen JL, Hokland P. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. Eur J Haematol 2001; 67:302-8.
11. Radich JP, Gooley T, Bryant E, Chauncey T, Clift R, Beppu L, et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late", 18 months or more after transplantation. Blood 2001;98:1701-7.
12. Muller MC, Hordt T, Paschka P, Merx K, La Rosee P, Hehlmann R, et al. Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia. Acta Haematol 2004;112:30-3.
13. Muller MC, Merx K, Weisser A, Kreil S, Lahaye T, Hehlmann R, et al. Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization. Leukemia 2002;16: 2395-9.
14. Livak KJ, Flood SJ, Marmaro J, Giusti W, Deetz K. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl 1995;4:357-62.
15. Barbany G, Hoglund M, Simonsson B. Complete molecular remission in chronic myelogenous leukemia after imatinib therapy. N Engl J Med 2002; 347:539-40.
16. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003;17:2474-86.
17. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004.
18. Hochhaus A, Weisser A, La Rosee P, Emig M, Muller MC, Saussele S, et al. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 2000;14:998-1005.
19. Breit S, Nees M, Schaefer U, Pfoersich M, Hagemeier C, Muckenthaler M, et al. Impact of pre-analytical handling on bone marrow mRNA gene expression. Br J Haematol 2004;126:231-43.
20. Melo JV, Yan XH, Diamond J, Lin F, Cross NC, Goldman JM. Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results. Leukemia 1996;10:1217-21.